A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms EMERALD
Sponsors Eisai Co Ltd

05 Sep 2024 According to an Eisai media release, data from this study will be presented in the ESMO Congress 2024 on September 16, 2024.
04 Jun 2024 Results assessing non-inferiority of eribulin to taxane when used in combination with dual HER2 blockade, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
15 Jul 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com